Analysis of efficacy and safety of ambroxol combined with antituberculosis therapy in the treatment of chronic obstructive pulmonary disease with pulmonary tuberculosis
Objective To explore the application effects of ambroxol combined with anti-tuberculosis therapy in the treatment of chronic obstructive pulmonary disease(COPD)with pulmonary tuberculosis.Methods Ninety-six patients with COPD complicated with pulmonary tuberculosis from January 2019 to June 2021 were selected.They were divided into a control group and a treatment group by using random number table method,48 in each group.The control group was treated with quadruple anti tuberculosis(2hrze/4hr regimen),and the treatment group was given ambroxol + 2HRZE/4HR regimen.At the end of 6 months after treatment,the anti-tuberculosis effect,pulmonary function,inflammation level and quality of life were compared between the two groups.The adverse reactionswererecorded.Results At the end of 6 months after treatment,the sputum negative conversion rate was 97.92%,the lesion significant absorption rate was 93.75%and the cavity narrowing closure rate was 89.58%in the treatment group,which were higher than those in the control group(P<0.05).The forced vital capacity(FVC),forced expiratory volume in 1s(FEV1),FEV1/FVC and peak expiratory flow rate(PEF)in both groups at the end of 6 months after treatment were increased compared to before treatment(P<0.05),and the FVC,FEV1,FEV1/FVC and PEF in treatment group were higher than those in the control group(P<0.05).Serum levels of C-reactive protein(CRP),interferon-γ(IFN-γ),interleukin-6(IL-6)and soluble interleukin-2 receptor(SIL2R)at the end of 6 months after treatment were decreased in both groups(P<0.05),and the levels were lower in treatment group compared to the control group(P<0.05).The scores of dimensions of St.George Respiratory Questionnaire(SGRQ)in the two groups were reduced at the end of 6 months after treatment(P<0.05),and the scores were lower in the treatment group(P<0.05).There were no statistical differences in the adverse reactions between the two groups(P>0.05).Conclusions Ambroxol in the treatment of patients with COPD and pulmonary tuberculosis can enhance the antituberculosis effect.It may be related to improving the pulmonary function and reducing the inflammation level.it is also conducive to improving the quality of life of patients with good safety.
Chronic obstructive pulmonary diseasePulmonary tuberculosisAmbroxolAntituberculous chemotherapyPulmonary function
NETL
NSTL
万方数据
